AbCellera Announces an Antibody Discovery Program in Influenza Vaccine Research
AbCellera announces a project with Sanofi Pasteur to apply its human antibody discovery and immune profiling technology for the research and development of next-generation influenza vaccines.
VANCOUVER, British Columbia, June 06, 2017 (GLOBE NEWSWIRE) -- AbCellera has entered into a collaborative research effort with Sanofi Pasteur, a global leader in the development and sale of vaccines for seasonal influenza. The project will use AbCellera's single-cell screening platform to profile vaccine-specific human antibodies elicited by seasonal influenza vaccination and to generate large panels of human monoclonal antibodies with desired binding profiles to various influenza strains.
Carl Hansen, CEO of AbCellera, commented, "AbCellera's platform is a powerful approach for human immune profiling and antibody discovery. We are excited to be working with the Sanofi Pasteur team to help advance vaccine research."
Seasonal influenza affects millions of people every year, and results in 250,000 to 500,000 deaths annually, according to the World Health Organization. Although vaccination provides protection when matched to the circulating strains, there is a place for new and improved vaccines when the circulating viruses do not match. Understanding the critical determinants that drive broad and protective human immune responses will guide the research and development of next-generation influenza vaccines.
AbCellera's microfluidic platform combines screening speed and throughput with unique capabilities for selecting antibodies with defined properties using a wide array of single-cell assays. This platform allows for in-depth screening of immune cells from human blood samples, and the rapid discovery and sequencing of large numbers of human monoclonal antibodies with desired binding properties across multiple antigens. The ability to rapidly annotate antibody sequences with functional data opens a new and important tool for vaccine research.
About AbCellera Biologics Inc.
AbCellera is a privately held company that develops next-generation monoclonal antibody therapies and provides enabling technologies to biotechnology and pharmaceutical partners. AbCellera's lead technology is a proprietary single-cell antibody discovery and immune profiling platform that allows for high-throughput screening of natural immune repertoires to rapidly identify lead therapeutic antibody candidates from any species, including humans.
Information om Nasdaq OMX
Følg pressemeddelelser fra Nasdaq OMX
Skrive dig op her og du vil løbende modtage pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Nasdaq OMX
Bermuda Business Development Agency (BDA)20.2.2018 16:38 | pressemeddelelse
Bermuda Principles event merges science and business
Elite Capital & Co. Limited20.2.2018 15:43 | pressemeddelelse
Elite Capital & Co. awarded Infrastructure Project Finance Provider 2018 by New European Economy
Corel20.2.2018 15:28 | pressemeddelelse
New MindManager 11 for Mac: Visually Capture, Organize, and Share Information to Drive Project and Business Success
Cisco20.2.2018 14:02 | pressemeddelelse
Cisco Leadership In Automation Continues With New Network Automation Portfolio for Service Providers
3D Signatures Inc.20.2.2018 14:02 | pressemeddelelse
3D Signatures Inc. Announces Positive Topline Results of Development Trial Assessing its Telo-HL(TM) Test for Hodgkin's Lymphoma
Crown Bioscience Inc.20.2.2018 14:02 | pressemeddelelse
Crown Bioscience Inc.: CAR T-Cell Therapy Platform
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum